Skip to main content

EB3 Antibody Blocking Peptide

Novus Biologicals, part of Bio-Techne | Catalog # NB100-56441PEP

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NB100-56441PEP

Key Product Details

Conjugate

Unconjugated

Applications

Antibody Competition

Product Specifications

Description

Application Notes

This peptide is useful as a blocking peptide for NB100-56441. For further blocking peptide related protocol, click here.

Specificity

This peptide is specific for NB100-56441 only.

Protein / Peptide Type

Antibody Blocking Peptide

Formulation, Preparation and Storage

NB100-56441PEP
Formulation Peptide dissolved in dH20. Contains no BSA.
Preservative No Preservative
Concentration 1 mg/ml
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store at -80C. Avoid freeze-thaw cycles.

Background: EB3

EB3 is a 282 amino acid homologue of EB1, a protein known to bind APC (adenomatous polyposis coli). It has been shown to bind to tubulin in vitro and microtubules in vivo. Northern blotting shows expressions to be mainly in brain, and to a lesser degree in muscle. EB3 interacts with APCL, a homologue of the tumor suppressor APC, and this interaction may be involved in the stabilization or extension of microtubules.

Alternate Names

EB1 protein family member 3, EB3EBF3-S, End-binding protein 3, microtubule-associated protein RP/EB family member 3, microtubule-associated protein, RP/EB family, member 3, RP3EBF3APC binding protein

Gene Symbol

MAPRE3

Additional EB3 Products

Product Documents for EB3 Antibody Blocking Peptide

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for EB3 Antibody Blocking Peptide

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...